New 100-week data from the ongoing Phase I/II study of zigakibart, an investigational anti-APRIL monoclonal antibody, ...

As CIDP moves toward targeted therapies and patient-friendly regimens, the market is primed for disruption—offering a fresh ...

A new trial finds that intravenous immunoglobulin stabilises kidney function and slows damage in patients with chronic ...

Though they are both multiple myeloma drugs with the same mechanism of action, Sanofi’s Sarclisa has had difficulty competing ...

The FDA has accepted for Priority Review the BLA for sibeprenlimab for the treatment of immunoglobulin A nephropathy in adults.

Current treatment options include utilizing anticoagulation and intravenous immunoglobulin to inhibit antibody-mediated platelet activation, by blocking FcγRIIA (immunoglobulin gamma Fc region ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Aim: To report on the efficacy and safety of elective switching from intravenously (IV) to subcutaneously (SC) administered Infliximab (IFX) in patients with immune mediated diseases. Methods: ...

Several patients commented on the convenience of subcutaneous immunoglobulin treatment with prefilled syringes administered via manual push. Subcutaneous immunoglobulin delivery using prefilled ...

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately ...